Marshall Urges House to Deliver Real Solutions for American Patients

December 12, 2019
Press Release

WASHINGTON, D.C. - Today, Congressman Roger Marshall, M.D., voted NO on H.R. 3, a government price-fixing bill that would decimate private research and development for future lifesaving treatments.

“American patients deserve access to new medicine that is going to treat, and maybe even cure, Alzheimer’s, diabetes, or cancer,” said Rep. Marshall. “We need to make sure a miracle drug, the one that could save your life, is available quickly and not stuck in an approval backlog. This short-sighted partisan bill passed by the House today would prevent patients from accessing future life-saving medicine and has no chance of becoming law.”

The Council of Economic Advisors recently estimated that H.R. 3 could lead to as many as 100 fewer drugs entering the market over the next decade, reducing population health and longevity. The Congressional Budget Office had similar estimates on reductions in innovation. Of the 270 drugs that have come to market since 2011, over 90 percent are available to patients in America compared to 8 percent in China, 33 percent in Australia, 48 percent in Canada, and 67 percent in the United Kingdom.

Both sides of the aisle had been working together on various proposals to bring more competition and more affordable prescription drugs to market. However, efforts were stalled by partisan politics and the introduction of Speaker Pelosi’s H.R. 3. Dr. Marshall participated in a special order Wednesday evening advocating for his colleagues across the aisle to rejoin efforts on delivering good, bipartisan policies for patients in Kansas and across the country.

“Congress should recognize the need for strong, bipartisan solutions with staying power and one of them is H.R. 19, the Lower Costs, More Cures Act,” said Rep. Marshall “This bill, crafted alongside our Democratic colleagues, contains over 40 bipartisan proposals that would lower out-of-pocket costs, protect access to new medicines and cures, strengthen transparency, and champion competition. If we work together, we can lower drug costs without destroying innovation.”

H.R. 19, the Lower Costs, More Cures Act:

  • Lowers the cost of prescription drugs by promoting low-cost options for patients and curbing the gaming of the system by drug companies, all the while encouraging innovation of groundbreaking new cures;
  • For the first time, places a cap on seniors’ out-of-pocket drug costs and allows them to manage their annual out-of-pocket spending;
  • Makes insulin more affordable;
  • Increases transparency and removes uncertainty at the pharmacy counter;
  • Cuts the cost of drug administration, including cancer treatment, for Medicare beneficiaries by as much as 50 percent;
  • Stops subsidizing other developed countries’ health care through stronger trade agreements with real enforcement mechanisms; and
  • Includes policy that has bipartisan, bicameral support and could be signed into law today.

To learn more about H.R. 19, the Lower Costs, More Cures Act, click here


Office Locations